Company: LGNZZ
Filing Date: 2025-04-17
Form Type: 8-K
Source: 0000886163-25-000020
Chunk: 2

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-17
Form: 8-K
Item: Item 9.01
Chunk 2
---
 of economic conditions, recession and inflationary measures; as well as other statements that are not historical in nature. You should be aware that failure to meet expectations with regard to any of the foregoing matters could negatively affect our results of operations, financial condition and the trading price of our stock.

The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-

looking statements, which reflect our good-faith beliefs (or those of indicated third parties) and speak only as of the date of this report. Except as required by law, we disclaim any intent or obligation to update these forward-looking statements beyond the date of this report, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended. Additional information concerning these and other risk factors affecting Ligand can be found in our public periodic filings with the Securities and Exchange Commission available at www. sec. gov.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                            LIGAND PHARMACEUTICALS INCORPORATED       
  Date: April 17, 2025      By: /s/ Andrew Reardon